Revelation Ebitda from 2010 to 2025

REVBW Stock  USD 0.02  0.0001  0.59%   
Revelation Biosciences EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -90 K in 2025. During the period from 2010 to 2025, Revelation Biosciences EBITDA regression line of quarterly data had mean square error of 14.4 T and geometric mean of  22,880. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-85.7 K
Current Value
-90 K
Quarterly Volatility
3.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Revelation Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revelation Biosciences' main balance sheet or income statement drivers, such as Other Operating Expenses of 7 M, Total Operating Expenses of 7 M or Total Other Income Expense Net of 10.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.79. Revelation financial statements analysis is a perfect complement when working with Revelation Biosciences Valuation or Volatility modules.
  
Check out the analysis of Revelation Biosciences Correlation against competitors.
For more information on how to buy Revelation Stock please use our How to Invest in Revelation Biosciences guide.

Latest Revelation Biosciences' Ebitda Growth Pattern

Below is the plot of the Ebitda of Revelation Biosciences over the last few years. It is Revelation Biosciences' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revelation Biosciences' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Revelation Ebitda Regression Statistics

Arithmetic Mean(1,451,620)
Geometric Mean22,880
Coefficient Of Variation(267.54)
Mean Deviation2,483,741
Median(3,640)
Standard Deviation3,883,622
Sample Variance15.1T
Range11.9M
R-Value(0.33)
Mean Square Error14.4T
R-Squared0.11
Significance0.21
Slope(272,222)
Total Sum of Squares226.2T

Revelation Ebitda History

2025-90 K
2024-85.7 K
2023-95.2 K
2022-10.8 M
2021-11.9 M
2020-145.5 K

About Revelation Biosciences Financial Statements

Revelation Biosciences investors use historical fundamental indicators, such as Revelation Biosciences' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Revelation Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-85.7 K-90 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Revelation Stock Analysis

When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.